News Lantheus on POINT in radio-oncology with $2bn licensing deal Lantheus' pipeline-building drive in radiopharma has continued with a $260 million upfront deal to license rights to two oncology candidates from POINT Biopharma.
R&D Health Innovators – Jennifer Schranz In the rare and ultra-rare disease space, the paucity of both data and patients makes everything about research and development more complicated.
R&D Inside the new world of healthcare data These days, real-world data collection is in vogue and not hard to come by in healthcare research.